{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:47:31Z","timestamp":1790484451101,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"24","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,6,17]]},"DOI":"10.1038\/s41388-021-01834-1","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T14:42:58Z","timestamp":1622817778000},"page":"4137-4150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Targeting the p300\/NONO axis sensitizes melanoma cells to BRAF inhibitors"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6137-4888","authenticated-orcid":false,"given":"Feifei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8805-4174","authenticated-orcid":false,"given":"Tiebang","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-0663","authenticated-orcid":false,"given":"Guofu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-1996","authenticated-orcid":false,"given":"Xiao-Bin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"1834_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrm3979","volume":"16","author":"H Lavoie","year":"2015","unstructured":"Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16:281\u201398.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1834_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrc.2017.79","volume":"17","author":"Z Karoulia","year":"2017","unstructured":"Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer. 2017;17:676\u201391.","journal-title":"Nat Rev Cancer"},{"key":"1834_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1947601911407323","volume":"2","author":"D Matallanas","year":"2011","unstructured":"Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer. 2011;2:232\u201360.","journal-title":"Genes Cancer"},{"key":"1834_CR4","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network.","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"1834_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014;14:455\u201367.","journal-title":"Nat Rev Cancer"},{"key":"1834_CR6","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1158\/0008-5472.CAN-10-0646","volume":"70","author":"H Yang","year":"2010","unstructured":"Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010;70:5518\u201327.","journal-title":"Cancer Res"},{"key":"1834_CR7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nature09627","volume":"468","author":"CM Johannessen","year":"2010","unstructured":"Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468:968\u201372.","journal-title":"Nature"},{"key":"1834_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1084\/jem.20171960","volume":"215","author":"A Saei","year":"2018","unstructured":"Saei A, Palafox M, Benoukraf T, Kumari N, Jaynes PW, Iyengar PV, et al. Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. J Exp Med. 2018;215:1913\u201328.","journal-title":"J Exp Med"},{"key":"1834_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387\u201390.","journal-title":"Nature"},{"key":"1834_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","volume":"4","author":"TJ Parmenter","year":"2014","unstructured":"Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Disco. 2014;4:423\u201333.","journal-title":"Cancer Disco"},{"key":"1834_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1158\/0008-5472.CAN-17-1318","volume":"78","author":"M Diaz-Martinez","year":"2018","unstructured":"Diaz-Martinez M, Benito-Jardon L, Alonso L, Koetz-Ploch L, Hernando E, Teixido J. miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma. Cancer Res. 2018;78:1017\u201330.","journal-title":"Cancer Res"},{"key":"1834_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06951-2","volume":"9","author":"S Corre","year":"2018","unstructured":"Corre S, Tardif N, Mouchet N, Leclair HM, Boussemart L, Gautron A, et al. Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nat Commun. 2018;9:4775.","journal-title":"Nat Commun"},{"key":"1834_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04664-0","volume":"9","author":"A Talebi","year":"2018","unstructured":"Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R, et al. Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nat Commun. 2018;9:2500.","journal-title":"Nat Commun"},{"key":"1834_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell. 2015;28:370\u201383.","journal-title":"Cancer Cell"},{"key":"1834_CR15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.isci.2019.06.001","volume":"16","author":"R Janostiak","year":"2019","unstructured":"Janostiak R, Malvi P, Wajapeyee N. Anaplastic lymphoma kinase confers resistance to BRAF kinase inhibitors in melanoma. iScience. 2019;16:453\u201367.","journal-title":"iScience"},{"key":"1834_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jnci\/djx198","volume":"110","author":"V Audrito","year":"2018","unstructured":"Audrito V, Manago A, La Vecchia S, Zamporlini F, Vitale N, Baroni G. et al. Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-mutated metastatic melanoma. J Natl Cancer Inst. 2018;110:290\u2013303.","journal-title":"J Natl Cancer Inst"},{"key":"1834_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1101\/gad.305854.117","volume":"32","author":"M Ohanna","year":"2018","unstructured":"Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, et al. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes Dev. 2018;32:448\u201361.","journal-title":"Genes Dev"},{"key":"1834_CR18","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","volume":"68","author":"C Montagut","year":"2008","unstructured":"Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008;68:4853\u201361.","journal-title":"Cancer Res"},{"key":"1834_CR19","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/nature09626","volume":"468","author":"R Nazarian","year":"2010","unstructured":"Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973\u20137.","journal-title":"Nature"},{"key":"1834_CR20","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1111\/jcmm.15141","volume":"24","author":"P Feng","year":"2020","unstructured":"Feng P, Li L, Deng T, Liu Y, Ling N, Qiu S, et al. NONO and tumorigenesis: more than splicing. J Cell Mol Med. 2020;24:4368\u201376.","journal-title":"J Cell Mol Med"},{"key":"1834_CR21","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1093\/nar\/gkw271","volume":"44","author":"GJ Knott","year":"2016","unstructured":"Knott GJ, Bond CS, Fox AH. The DBHS proteins SFPQ, NONO and PSPC1: a multipurpose molecular scaffold. Nucleic Acids Res. 2016;44:3989\u20134004.","journal-title":"Nucleic Acids Res"},{"key":"1834_CR22","doi-asserted-by":"publisher","first-page":"eaaw9960","DOI":"10.1126\/sciadv.aaw9960","volume":"6","author":"Y Qin","year":"2020","unstructured":"Qin Y, Chen W, Jiang G, Zhou L, Yang X, Li H, et al. Interfering MSN-NONO complex-activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer. Sci Adv. 2020;6:eaaw9960.","journal-title":"Sci Adv"},{"key":"1834_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/onc.2015.197","volume":"35","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Zhao X, Zhao L, Yang H, Liu L, Li J, et al. p54(nrb)\/NONO regulates lipid metabolism and breast cancer growth through SREBP-1A. Oncogene. 2016;35:1399\u2013410.","journal-title":"Oncogene"},{"key":"1834_CR24","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hep.31062","volume":"72","author":"Z Hu","year":"2020","unstructured":"Hu Z, Dong L, Li S, Li Z, Qiao Y, Li Y, et al. Splicing regulator p54(nrb) \/non-POU domain-containing octamer-binding protein enhances carcinogenesis through oncogenic isoform switch of MYC box-dependent interacting protein 1 in hepatocellular carcinoma. Hepatology. 2020;72:548\u201368.","journal-title":"Hepatology"},{"key":"1834_CR25","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1002\/jcp.26269","volume":"233","author":"L Alfano","year":"2018","unstructured":"Alfano L, Caporaso A, Altieri A, Costa C, Forte IM, Iannuzzi CA, et al. NONO ubiquitination is mediated by FBW7 and GSK3 beta via a degron lost upon chromosomal rearrangement in cancer. J Cell Physiol. 2018;233:4338\u201344.","journal-title":"J Cell Physiol"},{"key":"1834_CR26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/nar\/gky1166","volume":"47","author":"R Deshar","year":"2019","unstructured":"Deshar R, Yoo W, Cho EB, Kim S, Yoon JB. RNF8 mediates NONO degradation following UV-induced DNA damage to properly terminate ATR-CHK1 checkpoint signaling. Nucleic Acids Res. 2019;47:762\u201378.","journal-title":"Nucleic Acids Res"},{"key":"1834_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","volume":"18","author":"J Villanueva","year":"2010","unstructured":"Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K. Cancer Cell. 2010;18:683\u201395.","journal-title":"Cancer Cell"},{"key":"1834_CR28","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/carcin\/bgr103","volume":"32","author":"S Schiffner","year":"2011","unstructured":"Schiffner S, Zimara N, Schmid R, Bosserhoff AK. p54nrb is a new regulator of progression of malignant melanoma. Carcinogenesis. 2011;32:1176\u201382.","journal-title":"Carcinogenesis"},{"key":"1834_CR29","doi-asserted-by":"publisher","first-page":"36410","DOI":"10.1074\/jbc.M110.142307","volume":"285","author":"JH Jun","year":"2010","unstructured":"Jun JH, Yoon WJ, Seo SB, Woo KM, Kim GS, Ryoo HM, et al. BMP2-activated Erk\/MAP kinase stabilizes Runx2 by increasing p300 levels and histone acetyltransferase activity. J Biol Chem. 2010;285:36410\u20139.","journal-title":"J Biol Chem"},{"key":"1834_CR30","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","volume":"29","author":"N Wagle","year":"2011","unstructured":"Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29:3085\u201396.","journal-title":"J Clin Oncol"},{"key":"1834_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Disco. 2014;4:80\u201393.","journal-title":"Cancer Disco"},{"key":"1834_CR32","doi-asserted-by":"publisher","first-page":"9771","DOI":"10.1093\/nar\/gku650","volume":"42","author":"S Li","year":"2014","unstructured":"Li S, Li Z, Shu FJ, Xiong H, Phillips AC, Dynan WS. Double-strand break repair deficiency in NONO knockout murine embryonic fibroblasts and compensation by spontaneous upregulation of the PSPC1 paralog. Nucleic Acids Res. 2014;42:9771\u201380.","journal-title":"Nucleic Acids Res"},{"key":"1834_CR33","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/nar\/gkw1209","volume":"45","author":"L Jaafar","year":"2017","unstructured":"Jaafar L, Li Z, Li S, Dynan WS. SFPQ*NONO and XLF function separately and together to promote DNA double-strand break repair via canonical nonhomologous end joining. Nucleic Acids Res. 2017;45:1848\u201359.","journal-title":"Nucleic Acids Res"},{"key":"1834_CR34","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/onc.2015.107","volume":"35","author":"L Alfano","year":"2016","unstructured":"Alfano L, Costa C, Caporaso A, Altieri A, Indovina P, Macaluso M, et al. NONO regulates the intra-S-phase checkpoint in response to UV radiation. Oncogene. 2016;35:567\u201376.","journal-title":"Oncogene"},{"key":"1834_CR35","doi-asserted-by":"publisher","first-page":"6746","DOI":"10.1093\/nar\/gkp741","volume":"37","author":"S Li","year":"2009","unstructured":"Li S, Kuhne WW, Kulharya A, Hudson FZ, Ha K, Cao Z, et al. Involvement of p54(nrb), a PSF partner protein, in DNA double-strand break repair and radioresistance. Nucleic Acids Res. 2009;37:6746\u201353.","journal-title":"Nucleic Acids Res"},{"key":"1834_CR36","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl J Med. 2012;367:1694\u2013703.","journal-title":"N. Engl J Med"},{"key":"1834_CR37","doi-asserted-by":"publisher","first-page":"84951","DOI":"10.18632\/oncotarget.13069","volume":"7","author":"M Liu","year":"2016","unstructured":"Liu M, Xu S, Wang Y, Li Y, Zhang H, Liu H, et al. PD 0332991, a selective cyclin D kinase 4\/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Oncotarget. 2016;7:84951\u201364.","journal-title":"Oncotarget"},{"key":"1834_CR38","doi-asserted-by":"publisher","first-page":"C131","DOI":"10.4103\/0973-1482.200613","volume":"12","author":"K Zhang","year":"2016","unstructured":"Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer. J Cancer Res Ther. 2016;12:C131\u20137.","journal-title":"J Cancer Res Ther"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-021-01834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-021-01834-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-021-01834-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:22:33Z","timestamp":1684617753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01834-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":38,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2021,6,17]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01834-1","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"5 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional ethical review boards of the Third Affiliated Hospital of Nanchang University (ZKY2020025).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}